

July 16, 2025

To,

BSE Limited

Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051

Scrip code: 512529

Symbol: SEQUENT

Subject: Notice of 40th Annual General Meeting (“AGM”) and Annual Report for the FY 2024-25

Pursuant to Regulation 30 and 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following documents for your reference:

1. The Notice of the 40th AGM.
2. The Annual Report for FY 2024-25.

Following is the key information regarding the 40th Annual General Meeting:

1. The Annual General Meeting is scheduled to be held on Friday, August 08, 2025, at 4.00 p.m. (IST) through Video Conferencing / Other Audio-Visual Means.
2. The Notice of the Annual General Meeting is available on the Company's website at www.sequent.in. The same can be accessed at [Financial Overview - SeQuent](#).
3. The Company has provided the e-voting facility to its shareholders to exercise their voting rights on the resolutions set forth in the AGM Notice
4. The cut-off date for determining the eligibility to vote by remote e-voting or by e-voting system at the AGM shall be Friday, August 01, 2025. Details of the remote e-voting details are as under:

Remote E-voting start time and date	9:00 A.M. (IST) on Monday, August 4, 2025
Remote E-voting end time and date	5:00 P.M. (IST) on Thursday, August 07, 2025

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

5. The e-voting facility will also be available during the AGM. Shareholders attending the AGM through VC facility who are unable cast their vote by remote e-voting will be able to vote during the AGM.

You are requested to kindly take the same on record.

For Sequent Scientific Limited

Yoshita Vora
Company Secretary & Compliance Officer

Encl: As Above

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

SeQuent Scientific Limited

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana, India.

Tel No.: 91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: www.sequent.in | **Email:** investorrelations@sequent.in

NOTICE

NOTICE is hereby given that the Fortieth Annual General Meeting ('AGM') of the Members of SeQuent Scientific Limited (the '**Company**') will be held on, Friday, August 8, 2025, at 4:00 P.M. (IST) through Video Conferencing ('**VC**') / Other Audio-Visual Means ('**OAVM**') to transact the following businesses:

Ordinary Business:

Item No. 1: Adoption of Audited Financial Statements for the Financial Year ended March 31, 2025

To receive, consider, approve and adopt:

- a) the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2025, together with the reports of Board of Directors and Auditors thereon; and
- b) the Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2025, and the report of the Auditors thereon.

Item No. 2: Appointment of Director

To re-appoint Mr. Rajaram Narayanan (DIN: 02977405), Managing Director and Chief Executive Officer who retires by rotation and being eligible, offers himself for re-appointment.

Item No. 3: Appointment of Director

To re-appoint Mr. Neeraj Bharadwaj (DIN: 01314963), Non-Executive Director who retires by rotation and being eligible, offers himself for re-appointment.

Special Business:

Item No. 4: Ratification of Remuneration payable to the Cost Auditor for the Financial Year 2025-2026

To consider and if thought fit, to pass, the following resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 148 and all other applicable provisions, if any, of the Companies Act, 2013 read with Companies (Audit and Auditors) Rules 2014 and Companies (Cost Records and Audit) Rules, 2014 (including any statutory modification or re-enactment thereof for the time being in force) and subject to such other approvals, consents and permissions, if required, the remuneration of ₹ 1,50,000 (Rupees One Lakh Fifty Thousand only) plus applicable tax and re-imbursement of out-of-pocket expenses payable to M/s. Joshi Apte & Associates, Practicing Cost Accountants, (Firm Registration Number: 000240) who was appointed by the Board of Directors of the Company to conduct the audit of the cost records of the Company for the financial year ending March 31, 2026, be and is hereby ratified and confirmed.

RESOLVED FURTHER THAT any of the Directors or Company Secretary of the Company be and are hereby authorised to do all such acts, deeds, matters and things as may be deemed necessary, desirable, proper or expedient for the purpose of giving effect to the above Resolution."

Item No.5: Appointment of M/s BMP & Co. LLP, Practicing Company Secretaries, as the Secretarial Auditor of the Company for a term of five consecutive years from the Financial Year 2025-26 to the Financial Year 2029-30

To consider and, if thought fit, to pass, the following Resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and the Regulation 24A(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment thereof for the time being in force), M/s BMP & Co. LLP, Practicing Company Secretaries (Firm Registration Number: L2017KR003200) be and are hereby appointed as Secretarial Auditors of the Company, for a term of five (5) consecutive years, to hold office of the Secretarial Auditor for the Financial Year 2025-26 up to Financial Year 2029-30, on such remuneration, as may be mutually agreed between the Board of Directors of the Company and the Secretarial Auditors, from time to time.



RESOLVED FURTHER THAT any of the Directors and the Company Secretary of the Company, be and are hereby severally authorized to take such steps and do all such acts, deeds, matters and things as may be considered necessary, proper and expedient to give effect to this Resolution."

Item No.6: Payment of commission to Non-Executive Directors (including Independent Directors) of the Company

To consider and, if thought fit, to pass, the following Resolution as an **Ordinary Resolution**:

"RESOLVED THAT pursuant to the provisions of Section 149, 197, 198 and all other applicable provisions, if any, of the Companies Act, 2013 (the 'Act') and the rules made thereunder read with Schedule V of the Act (including any amendment(s), statutory modification(s) or re-enactment(s) thereof for the time being in force), Regulation 17(6)(a) and all other applicable provisions, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') or any other law for the time being in force, and in accordance with provisions of the Articles of Association of the Company, pursuant to the recommendations of Nomination and Remuneration Committee and the Board of Directors of the Company and subject to such other approvals as may be required in this regard, the approval of the members of the Company be and is hereby accorded to pay remuneration by way of commission to Non-Executive Directors (including Independent Directors) notwithstanding the profits / absence of profits / inadequacy of profits in the Company within the limit specified in Part II, Section II, item (A) of Schedule V of the Act and such commission be paid to the said Non-Executive Directors (including Independent Directors) of the Company in such amounts or proportions and in such manner as may be determined by the Board of Directors of the Company for a period of three Financial Years i.e. FY 2025-26 to FY 2027-28 or such other time period as may be permitted under the Act.

RESOLVED FURTHER THAT the above remuneration shall be in addition to sitting fees payable to the Director(s) for attending the meetings of the Board or Committees thereof or for any other purpose whatsoever as may be decided by the Board of Directors and reimbursement of expenses for participation in the Board and other meetings.

RESOLVED FURTHER THAT the any of the Directors or any Committee thereof be and is hereby authorized to take all such steps as may be necessary for obtaining any approvals, statutory, contractual or otherwise, in relation to the above, and to do all the acts, deeds, matters and things which are necessary, proper, expedient and incidental for giving effect to this resolution."

Item No.7: Approval for remuneration payable to Mr. Rajaram Narayanan (DIN: 02977405), Managing Director and Chief Executive Officer of the Company

To consider and if thought fit, to pass the following resolution as a **Special Resolution**:

"RESOLVED THAT in furtherance to the approval by the Members through postal ballot on April 9, 2022, the Thirty Ninth Annual General Meeting of the Company and pursuant to the provisions of Sections 196, 197, 203 and other applicable provisions of the Companies Act, 2013 ("Act") and the rules made thereunder (including any statutory modification or re-enactment thereof for the time being in force) read with Schedule V of the Act, applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) as amended, and provisions of Articles of Association of the Company and as recommended by the Nomination and Remuneration Committee and approved by the Board of Directors, consent of the Members of the Company be and is hereby accorded for the payment of remuneration to Mr. Rajaram Narayanan, Managing Director & CEO of the Company for the period starting from April 1, 2025 to April 10, 2027 along with perquisites as mentioned in the explanatory statement.

RESOLVED FURTHER THAT in case of inadequacy of profits, such remuneration comprising salary, perquisites and benefits, as approved hereinabove, be paid as minimum remuneration in accordance with Section 197 read with Schedule V of the Act.

RESOLVED FURTHER THAT the any of the Directors or any Committee thereof be and is hereby authorized to take all such steps as may be necessary for obtaining any approvals, statutory, contractual or otherwise, in relation to the above, and to do all the acts, deeds, matters and things which are necessary, proper, expedient and incidental for giving effect to this resolution."

Item No.8: Re-appointment of Dr. Kamal Sharma (DIN: 00209430) as an Independent Director for a second term of five consecutive years from August 25, 2025 to August 24, 2030

To consider and, if thought fit, to pass, the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 and other applicable provisions, if any, of the Companies Act, 2013 ("Act") read with Schedule IV to the Act and the Companies (Appointment and Qualification of Directors) Rules, 2014, read with Regulations 17(1A), 25 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") (including any statutory modification(s) or re-enactment thereof for the time being in force), the Articles of Association of the Company and pursuant to the recommendation of the Nomination and Remuneration Committee and the Board of Directors, Dr. Kamal Sharma (DIN: 00209430), who holds office of Independent Director up to August 24, 2025 and who has submitted a declaration that he meets the criteria for independence as provided under Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations and in respect of whom the Company has received a notice in writing under Section 160(1) of the Act, from a Member, signifying intention to propose his candidature for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, for a second term of five consecutive years from August 25, 2025 to August 24, 2030, notwithstanding that Dr. Kamal Sharma had attained the age of seventy-five years during his first term as an Independent Director.

RESOLVED FURTHER THAT any of the Directors, the Chief Financial Officer and the Company Secretary of the Company, be and are hereby severally authorized to take such steps and do all such acts, deeds, matters and things as may be considered necessary, proper and expedient to give effect to this Resolution."

Item No.9: Re-appointment of Mr. Milind Sarwate (DIN: 00109854) as an Independent Director for a second term of five consecutive years from August 25, 2025 to August 24, 2030

To consider and, if thought fit, to pass, the following Resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 and other applicable provisions, if any, of the Companies Act, 2013 ("Act") read with Schedule IV to the Act and the Companies (Appointment and Qualification of Directors) Rules, 2014, read with Regulations 17, 25 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") (including any statutory modification(s) or re-enactment thereof for the time being in force), the Articles of Association of the Company and pursuant to the recommendation of the Nomination and Remuneration Committee and the Board of Directors, Mr. Milind Sarwate (DIN: 00109854), who holds office of Independent Director up to August 24, 2025 and who has submitted a declaration that he meets the criteria for independence as provided under Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations and in respect of whom the Company has received a notice in writing under Section 160(1) of the Act, from a Member, signifying intention to propose his candidature for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, for a second term of five consecutive years from August 25, 2025 to August 24, 2030.

RESOLVED FURTHER THAT any of the Directors, the Chief Financial Officer and the Company Secretary of the Company, be and are hereby severally authorized to take such steps and do all such acts, deeds, matters and things as may be considered necessary, proper and expedient to give effect to this Resolution."

By order of the Board of Directors of
SeQuent Scientific Limited

Yoshita Vora

Company Secretary & Compliance Officer
Membership No.: ACS 22220

Date: July 13, 2025
Place: Thane



NOTES:

1. Pursuant to the General Circular No. 09/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs (MCA) and Circular SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 issued by SEBI along with other circulars issued by MCA and SEBI from time to time (hereinafter collectively referred to as "the Circulars"), companies are allowed to hold AGM through VC, without the physical presence of members at a common venue. Hence, in compliance with the Circulars, the AGM of the Company is being held through VC.
2. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 ("the Act") and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") the explanatory statement in relation to Item No. 4, Item No. 5, Item No. 6, Item No. 7, Item No. 8 and Item No. 9 of the Notice, forms part of this Notice.
3. The other details pursuant to provisions of Secretarial Standard 2 ("SS 2") on General Meeting Issued by the Institute of Company Secretaries of India and the Listing Regulations, forms part of this Notice and enclosed as **Annexure A and B**.
4. In line with the Circulars, the notice of the 40th AGM along with the Annual Report 2024-25 are being sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/ Depositories. Additionally, a letter providing the web-link, including the exact path, where complete details of the Annual Report is available is being sent to those Members who have not registered their email ID. Members may please note that the Notice and Annual Report 2024-25 will also be available on the Company's website at Investor Contacts - SeQuent and on the websites of the Stock Exchanges i.e. BSE Limited and NSE at www.bseindia.com and www.nseindia.com respectively, and on the website of NSDL, <https://www.evoting.nsdl.com>
5. **Pursuant to the provisions of the Act, a member entitled to attend and vote at a meeting is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a member of the Company. Since this AGM is being held through VC/OAVM pursuant to the Circulars, physical attendance of the Members has been dispensed with. Accordingly, in terms of the Circulars and the SEBI circulars, the facility for appointment of proxies by the members will not be available for this AGM and hence the proxy form and attendance slip are not annexed to this notice.**

Since the AGM will be held through VC/OAVM, the route map of the venue for the Meeting is not annexed hereto.

6. The Register of Directors and Key Managerial Personnel, their Shareholding, and the Register of Contracts or Arrangements in which the Directors are interested, certificate from the secretarial auditor of the Company under Regulation 13 of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 along with other documents as stated in the Notice of AGM will be available for inspection in electronic mode by the Members during the AGM without any fee from the date of circulation of this Notice up to the date of AGM during business hours i.e. from 9:00 am to 5:00 pm.

Members seeking to inspect such documents can send an e-mail to investorrelations@sequent.in

7. Members desirous of obtaining any information/ clarification on the financial statements or any of the resolutions as detailed in the Notice are requested to write to the Company on or before August 3, 2025 through an e-mail to investorrelations@sequent.in specifying his/her name along with Client ID/ DP ID or Folio No., as the case may be and the replies to these queries may be given by the Chairman/ Managing Director during the course of AGM or subsequently via e-mail.

8. KYC Updation

As per the SEBI Circular, the Company/ RTA can entertain a shareholder's service request only upon completion of the KYC viz., PAN, contact details, bank account details and specimen signature. The service requests are required to be submitted in the format prescribed by the SEBI

Members holding shares in electronic form are, therefore, requested to submit their PAN to the Depository Participants with whom they maintain their demat accounts.

Non-Resident Indian Members are requested to inform RTA/ respective Depository Participants, immediately of any:

- a) Change in their residential status on return to India for permanent settlement.
- b) Particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with pin code number, if not furnished earlier.

As per Listing Regulations, SEBI has mandated that all requests for transfer of securities including transmission and transposition requests shall be processed only in dematerialised form. In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialization, Members are advised to dematerialize the shares held by them in physical form. Members can contact the Company or the Company's RTA, for assistance in this regard.

To prevent fraudulent transactions, Members are advised to exercise due diligence and notify to their Depositories Participants (DPs) in respect of their electronic share accounts and to the Company's Registrar and Transfer Agent of any change in address or demise of any Member as soon as possible. Members are also advised not to leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned DPs and holdings should be verified from time to time.

9. Procedure for e-voting and joining AGM through VC/OAVM

In compliance with the provisions of Section 108 of the Act read with relevant rules, SS-2, Regulation 44 of the Listing Regulations and Circulars, the facility for remote e-voting and e-voting in respect of the business to be transacted at the AGM is being provided by the Company through National Securities Depository Limited (NSDL).

General instructions for accessing and participating in the AGM through VC/OAVM Facility and voting through electronic means including remote e-voting is annexed hereto as **Annexure-C**.

10. Scrutinizer for the AGM

The Company has appointed SGGS & Associates, Practicing Company Secretaries, represented by Mr. Gaurav Sainani (having Membership No. A36600 and COP No. 24482) or failing him Mr. Sunny Gogiya (having Membership No. A56804 and COP No. 21563) to scrutinize the remote e-voting process and e-voting done through VC at the AGM in a fair and transparent manner.

The Scrutinizer shall submit his report to the Chairman or the Company Secretary after completion of the scrutiny.

Results of the Meeting along with the Scrutinizers Report shall be declared by the Chairman or the Company Secretary within the timeline prescribed under the Listing Regulations and shall be displayed on the Company's website, besides being communicated to the Stock Exchanges, Depositories and Registrar and Transfer Agent.

11. Email Address Registration/Updating

Those Members who have not yet registered or updated their email addresses are requested to register or update their email addresses by following the procedure given below for receiving all the communications including annual report, notices, letters etc., in electronic mode from the Company:

- Members holding shares in Demat form may temporarily register their e-mail addresses with the RTA at einward.ris@kfintech.com or Company at investorrelations@sequent.in by providing details such as Name, DPID/Client ID, PAN, mobile number and e-mail ID. It is clarified that for permanent registration of e-mail address; the Members are requested to register the same with their respective Depository Participant.
- Members holding shares in physical form, are requested to register or update their email addresses by submitting physical copy of Form ISR-1 to the RTA at below mentioned address along with the scanned copy of Form ISR-1 to RTA at einward.ris@kfintech.com and the Company at investorrelations@sequent.in:

KFin Technologies Limited
(formerly known as KFin Technologies Private Limited)
Address : Selenium Building, Tower-B,
Plot No 31 & 32, Financial District,
Nanakramguda, Serilingampally,
Hyderabad, Rangareddy, Telangana, India - 500 032.
Email ID: einward.ris@kfintech.com
Toll Free / Phone Number: 1800 309 4001

ISR-1 Form can be downloaded from the web link: https://sequent.in/wp-content/pdf/downloads/Form%20ISR-1_p.pdf



12. KPRISM from KFintech, RTA

Members are requested to note that, our Registrar and Share Transfer Agents (KFintech/ RTA) have launched a mobile application - KPRISM and a website <https://kprism.kfintech.com/> for our investors. Now you can download the mobile app and see your portfolios serviced by KFintech.

Check Dividend status, request for annual reports, change of address, change / update Bank mandate and download standard forms. The android mobile application can be downloaded from Play Store by searching for "KPRISM".

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013

As required by Section 102(1) of the Companies Act, 2013 ('Act'), Secretarial Standard 2 and Listing Regulations the following explanatory statement sets out all the material facts relating to the business mentioned under Item No. 4, Item No. 5, Item No. 6, Item No. 7, Item No. 8 and Item No. 9 of the accompanying notice:

Item No. 4: Ratification of Remuneration payable to the Cost Auditor for the Financial Year 2025-2026

In terms of provisions of Section 148 (3) of the Companies Act, 2013 and the Companies (Cost records and audit) Rules, 2014 as notified by Ministry of Corporate Affairs, the Company is required to appoint a Cost Auditor for the financial year 2025-26 within one hundred and eighty days of the commencement of every financial year. In compliance with the same, the Board in its meeting held on May 20, 2025, appointed M/s. Joshi Apte & Associates, Practicing Cost Accountant, (Firm Registration Number: 000240) as Cost Auditor for the Financial Year 2025-2026 on a remuneration of ₹ 1,50,000 (Rupees One Lakh Fifty Thousand Only) per annum plus applicable taxes and out of pocket expenses on the recommendation of the Audit Committee of the Company.

As per Section 148 of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors as approved by the Board of Directors has to be ratified subsequently by the members of the Company. Accordingly, members' approval is sought by way of Ordinary Resolution for ratification of remuneration to M/s. Joshi Apte & Associates, Practicing Cost Accountant, for the Financial Year 2025-26.

None of the Directors and/or Key Managerial Personnel of the Company and/or their relatives, are in any way, concerned or interested (financially or otherwise) in the proposed Ordinary Resolution.

The Board recommends the **Ordinary Resolution** as set out in **Item No. 4** for approval by the Members.

Item No. 5: Appointment of Secretarial Auditors

In accordance with Section 204 of the Companies Act 2013, read with the Rules framed thereunder, and Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), every listed entity is required to undertake Secretarial Audit by a Peer Reviewed Secretarial Auditor who shall be appointed by the Members of the Company, on the recommendation of the Board of Directors, for a period of five consecutive years.

Based on the recommendation of the Audit Committee, the Board of Directors, at its Meeting held on May 20, 2025, subject to the approval of the Members of the Company, approved appointment of M/s. BMP & Co LLP, Company Secretaries (Firm Registration Number:L2017KR003200) as the Secretarial Auditors of the Company, for a term of five (5) consecutive years, to hold office of the Secretarial Auditor from the Financial Year 2025-26 up to Financial Year 2029-30. M/s. BMP & Co LLP is a firm of Practicing Company Secretaries having Two decades of rich experience in Listed companies, Mergers and amalgamation, Company Law and SEBI Regulations., FEMA Regulations including carrying out Secretarial Audits, Due Diligence Audits and Compliance Audits for various reputed companies. The firm is Peer Reviewed and Quality Reviewed by the Institute of the Company Secretaries of India.

M/s. BMP & Co LLP had consented to their appointment as the Secretarial Auditors of the Company and have confirmed that they fulfil the criteria as specified in Clause (a) of regulation 24A (1A) of the Listing Regulations and have not incurred any of disqualifications as specified by the Securities and Exchange Board of India. The proposed remuneration to be paid to M/s. BMP & Co LLP, for the financial year 2025-26 is ₹3,00,000/- (Rupees Three Lakh Only) plus out of pocket expenses and applicable taxes.

There is no material change in the fees payable to M/s. BMP & Co LLP from that paid to the previous Secretarial Auditor. Accordingly, consent of the Members is sought for approval of the aforesaid appointment of the Secretarial Auditors.

None of the Directors or Key Managerial Personnel of the Company and their relatives are concerned or interested, financially or otherwise, in this Resolution.

The Board recommends the **Ordinary Resolution** as set out in **Item No. 5** for approval by the Members.

Item No.6: Payment of commission to Non-Executive Directors (including Independent Directors) of the Company

The Members of the Company, through postal ballot on January 17, 2021, approved payment of commission to Non-Executive Directors (including Independent Directors) of the Company, up to 2% of the net profits of the Company calculated in accordance with Section 198 of the Companies Act, 2013 (the 'Act'), with effect from FY 2020-21 onwards. The Board of Directors was also authorized to determine the criteria for such payments.

Members may note that a Scheme of Amalgamation is currently in progress involving Sequent Scientific Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited and Sequent Research Limited, and their respective shareholders and creditors ("Scheme"). As a part of its implementation strategy, the Company will need to integrate the systems, resources, personnel, finances, operations, culture etc. for the combined entities once the Scheme is effective. In this regard, the Board of Directors will play a pivotal role in providing its expert opinion and guidance in the successful implementation of the said strategy.

The Non-Executive Directors (including Independent Directors) bring extensive professional experience and expertise in areas such as strategic leadership, technology, industry knowledge, financial and risk management, governance, international business, public policy, and social impact. In view of the value they add to the Board through their strategic guidance, oversight, and significant time commitment required at combined entity level, the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee and subject to shareholder approval, have approved the payment of remuneration to Non-Executive Directors (including Independent Directors) basis the limits specified against effective capital as per Section 197 of the Companies Act, 2013 read with Section II of Part II, Item A of Schedule V.

Section 197 read with Section II of Part II, Item A of Schedule V the Act, and Regulation 17(6)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') mandates shareholder approval by way of Ordinary Resolution for such payments.

The members may note that such remuneration shall not exceed the limits prescribed under Part II, Section II, Item A of Schedule V of the Act for a period of three financial years from FY 2025-26 to FY 2027-28 (or any such other period as may be permitted under the Act). This remuneration will be in addition to sitting fees for attending Board and Committee meetings. Such fees shall be paid, in case of the inadequacy of profits as minimum remuneration in such proportion as the Board may think fit. Members may further note that in case of adequate profits, remuneration as approved by the shareholders through postal ballot on January 17, 2021, may be paid subject to applicable laws.

The information required to be disclosed under paragraph (iv) of the second proviso after item B of Section II of Part II of Schedule V to the Act read with Secretarial Standard 2 on General Meeting issued by the Institute of Company Secretaries of India is given in the **Annexure-A and B** to this Notice. The Company has not defaulted in payment of dues to any bank or public financial institution or non-convertible debenture holders or other secured creditor, if any.

None of the Directors, Key Managerial Personnel and their relatives is, in any way, concerned or interested, financially or otherwise, except to the extent of their shareholdings in the Company, if any in the resolution as set out in Item no. 6 of the Notice.

Non-Executive Directors (including Independent Directors) of the Company, shall be deemed to be concerned or interested in resolution set out at Item no. 6 of the Notice to the extent of the remuneration that may be received by them in future.

The Board of Directors recommends the **Ordinary Resolution** set out at **Item no. 6** of the Notice for approval by the members.

Item No. 7: Approval for remuneration payable to Mr. Rajaram Narayanan (DIN: 02977405), Managing Director and Chief Executive Officer of the Company

Mr. Rajaram Narayanan, Managing Director and Chief Executive Officer (CEO) was appointed w.e.f. April 11, 2022. Considering the requirements of Section 197 read with Schedule V of the Companies Act, 2013, his remuneration was approved for only 3 years.

The members are informed that considering the performance of the Company, the Managing Director's contribution towards the growth, his increasing responsibilities and trend in the industry, and as per the Policy on the Director's Appointment and Remuneration, the Board of Directors of the Company at its meeting held on May 20, 2025, had pursuant to the recommendation of the Nomination and Remuneration Committee and



subject to the approval of the Members at the ensuing Annual General Meeting, approved the remuneration payable to Mr. Rajaram Narayanan, the Managing Director of the Company for period starting from April 1, 2025 to April 10, 2027 as detailed below:

Sr. No.	Particulars	Amount*
1	Basic Salary (1)	In the range of ₹ 1,40,00,000 p.a. to ₹ 2,00,00,000 p.a.
2	Other allowances (2)	In the range of ₹ 1,60,00,000 p.a. to ₹ 2,50,00,000 p.a.
3	Fixed remuneration (1+2)	In the range of ₹ 3,00,00,000 p.a. to ₹ 4,50,00,000 p.a.
4	Variable pay (Performance bonus)	Currently 40% of Fixed remuneration at target and subject to approvals from Nomination and Remuneration Committee and the Board of Directors.
6	Total remuneration (Fixed + Variable)	In the range of ₹ 4,20,00,000 p.a. to ₹ 6,30,00,000 p.a.
5	Retirals	As per Company's policy
6	Other benefits (Company car for business use, Housing/ HRA, Leave encashment, Insurance Medical, Reimbursements etc.)	As per Company's policy
7.	Employee Stock Option scheme	As per company policy and subject to approvals from Nomination and Remuneration Committee and the Board of Directors.

* includes remuneration to be paid from Alivira Animal Health Limited ("AAHL"), wholly owned subsidiary of the Company

The Board of Directors shall fix annual remuneration of the Managing Director within the above scale based on the recommendation of the Nomination and Remuneration Committee.

The above remuneration shall be paid from the Company and AAHL in the proportion as may be mutually decided by the Company and AAHL and approved by the Board. The proportionate annual remuneration from the Company and AAHL may be reviewed periodically by the Board. Based on such reviews and mutual agreement between the parties to the employment agreement, the proportion of the remuneration payable between each entity may be adjusted. This may include an increase in the total remuneration payable by the Company and a corresponding decrease in the remuneration from AAHL. Further, if, based on mutual agreement between Mr. Rajaram Narayanan and the Company, his employment with AAHL is terminated during the term of his employment with the Company, he will become entitled to receive the entire amount from the Company.

Pursuant to the provisions of Sections 196, 197, 198 and all other applicable provisions of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) read with Schedule V of the Act, the approval of the remuneration payable to Mr. Rajaram Narayanan is now being placed before the Members at the ensuing Annual General Meeting for their approval by way of a Special Resolution.

The Company has not committed any default in payment of dues to any bank or public financial institution or non-convertible debenture holders or any other secured creditor, if any.

Disclosure as required as per Secretarial Standard 2 on General Meetings issued by the Institute of Company Secretaries of India and the Listing Regulations is set out in **Annexure A** of this Notice. Further, disclosure under Schedule V of the Act is set out in **Annexure B** to this Notice.

Except Mr. Rajaram, none of the Director(s) and Key Managerial Personnel of the Company or their respective relatives, thereof, are concerned or interested, financially or otherwise in the Resolution mentioned at Item No. 7 of the Notice.

Mr. Rajaram has no other pecuniary relationship with the Company except to the extent of his remuneration and shareholding interest from the Company.

The Board recommends the **Special Resolution** as set out in **Item No. 7** for approval by the Members.

Item No.8: Re-appointment of Dr. Kamal Sharma (DIN: 00209430) as Independent Director for a second term of five consecutive years from August 25, 2025 to August 24, 2030

Dr. Kamal Sharma was appointed as an Independent Director of the Company for a term of 5 (Five) years with effect from August 25, 2020 pursuant to approval of shareholders through Postal Ballot on January 17, 2021.

Pursuant to the provisions of Section 149(10) of the Companies Act, 2013 (the 'Act') read with Regulation 25(2A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') an Independent Director shall be eligible for re-appointment for second term on passing of a special resolution by the Company.

Further, sub-regulation 17(1A) of the Listing Regulations mandates that no listed entity shall appoint a person or continue the directorship of any person as a Non-Executive Director who has attained the age of seventy-five years, unless a special resolution is passed to that effect.

It is to be noted that the shareholders of the Company, at its Thirty-seventh Annual General Meeting held on Tuesday, September 20, 2022, approved the continuation of Dr. Kamal Sharma as non-executive independent director of the company, on account of attaining the age of seventy-five years.

The Nomination & Remuneration Committee ('NRC'), after taking into account the performance evaluation of Dr. Kamal Sharma during his first term of five years and considering his knowledge, acumen, expertise, experience and substantial contribution and time commitment, has recommended to the Board his re-appointment for a second term of five years from August 25, 2025 to August 24, 2030.

The Board of Directors based on the recommendations of the Nomination and Remuneration Committee and subject to the approval of the Members of the Company, approved the re-appointment of Dr. Kamal Sharma as a Non-Executive Independent Director of the Company, not liable to retire by rotation, for a second term of five years from August 25, 2025 to August 24, 2030.

Dr. Kamal Sharma has confirmed his eligibility and has given his consent to act as Independent Director of the Company. The Company has received declarations from him confirming that (i) he meets the criteria of independence as provided in Section 149(6) of the Act and rules made thereunder & Regulation 16(1)(b) of Listing Regulations; (ii) he is not disqualified from being appointed as a Director in terms of Section 164 of the Act; (iii) he is not debarred from holding office of director pursuant to any order of SEBI, Ministry of Corporate Affairs or any such other Statutory Authority; and (iv) he is not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact his ability to discharge his duties with an objective independent judgment and without any external influence. Further, he has confirmed that he has successfully registered himself in the Independent Director's Databank maintained by the Indian Institute of Corporate Affairs in terms of the requirement of the Act.

The Company has also received a notice under Section 160 of the Act from a member proposing his candidature as an Independent Director of the Company as per the applicable provisions of the Act.

As an Independent Director, he shall be entitled to the remuneration in the form of commission and sitting fees for attending Board & Committee meeting(s), if any which shall be governed by Company's Policy and approval of the Board and members (as applicable) from time to time.

In the opinion of the Board, he fulfils the conditions specified in the Act, rules made thereunder and the Listing Regulations for re-appointment as an Independent Director of the Company and is independent of the management of the Company.

The detailed profile and specific expertise of Dr. Kamal Sharma as required under Regulation 36(3) of Listing Regulations and Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India are provided in **Annexure-A** of this Notice.

Except Dr. Kamal Sharma, being the proposed appointee, none of the Directors or Key Managerial Personnel of the Company or their relatives are in any way, financially or otherwise concerned or interested in the said Resolution except to the extent of their shareholding in the company, if any.

The Board recommends the passing of **Special Resolution** as set out at **Item No. 8** of the Notice for approval by the Member.



Item No. 9: Re-appointment of Mr. Milind Sarwate (DIN: 00109854) as an Independent Director for a second term of five consecutive years from August 25, 2025 to August 24, 2030

Mr. Milind Sarwate was appointed as an Independent Director of the Company for a term of 5 (Five) years with effect from August 25, 2020 pursuant to approval of shareholders through Postal Ballot on January 17, 2021.

Pursuant to the provisions of Section 149(10) of the Companies Act, 2013 (the 'Act') read with Regulation 25(2A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') an Independent Director shall be eligible for re-appointment for second term on passing of a Special Resolution by the Company.

The Nomination & Remuneration Committee ('NRC'), after taking into account the performance evaluation of Mr. Milind Sarwate during his first term of five years and considering his knowledge, acumen, expertise, experience and substantial contribution and time commitment, has recommended to the Board his re-appointment for a second term of five years from August 25, 2025 to August 24, 2030.

The Board of Directors, through Circular Resolution passed on July 12, 2025, based on the recommendations of the Nomination and Remuneration Committee and subject to the approval of the Members of the Company, approved the re-appointment of Mr. Milind Sarwate as a Non-Executive Director Independent of the Company, not liable to retire by rotation, for a second term of five years from August 25, 2025 to August 24, 2030.

Mr. Milind Sarwate has confirmed his eligibility and has given his consent to act as Independent Director of the Company. The Company has received declarations from him confirming that (i) he meets the criteria of independence as provided in Section 149(6) of the Act and rules made thereunder & Regulation 16(1)(b) of Listing Regulations; (ii) he is not disqualified from being appointed as a Director in terms of Section 164 of the Act; (iii) he is not debarred from holding office of director pursuant to any order of SEBI, Ministry of Corporate Affairs or any such other Statutory Authority; and (iv) he is not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact his ability to discharge his duties with an objective independent judgment and without any external influence. Further, he has confirmed that he has successfully registered himself in the Independent Director's Databank maintained by the Indian Institute of Corporate Affairs in terms of the requirement of the Act.

The Company has also received a notice under Section 160 of the Act from a member proposing his candidature as an Independent Director of the Company as per the applicable provisions of the Act.

As an Independent Director, he shall be entitled to the remuneration in the form of commission and sitting fees for attending Board & Committee meeting(s), if any which shall be governed by Company's Policy and approval of the Board and members (as applicable) from time to time.

In the opinion of the Board, he fulfils the conditions specified in the Act, rules made thereunder and the Listing Regulations for re-appointment as an Independent Director of the Company and is independent of the management of the Company.

The detailed profile and specific expertise of Mr. Milind Sarwate as required under Regulation 36(3) of Listing Regulations and Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India are provided in **Annexure-A** of this Notice.

Except Mr. Milind Sarwate, being the proposed appointee, none of the Directors or Key Managerial Personnel of the Company or their relatives are in any way, financially or otherwise concerned or interested in the said Resolution except to the extent of their shareholding in the company, if any.

The Board, therefore, recommends the approval of the **Special Resolution** set out at **item no. 9** of this Notice.

By order of the Board of Directors of
SeQuent Scientific Limited

Yoshita Vora

Company Secretary & Compliance Officer
Membership No.: ACS 22220

Date: July 13, 2025,
Place: Thane

ANNEXURE – A

Relevant details pursuant to Regulation 36(3) of the Listing Regulations and Secretarial Standard on General Meetings issued by Institute of Company Secretaries of India, is as given under:

a. Details of Mr. Rajaram Narayanan, Director of the Company:

Name of the Director	Mr Rajaram Narayanan
DIN	02977405
Age	57
Nationality	Indian
Date of first appointment on the Board	April 11, 2022
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	With over 25 years of experience, Mr. Narayanan has a strong track record of leading revenue and profitability growth across multiple industries including pharmaceuticals. He joined from Sanofi India Limited, where he was the Managing Director and Country Chair for India. At Sanofi, he led the strategic reorientation of its India business operations, resulting in accelerated growth in key therapies and significant transformation of Sanofi's market operations. Before Sanofi, he was Chief Marketing Officer at Airtel, India's leading telecommunications company. Mr. Narayanan started his career at Hindustan Unilever Ltd., where he held various leadership roles in India and other Asian markets for over 18 years, building and managing many iconic consumer brands.
Terms and conditions of appointment or Reappointment	Executive Non Independent Director Liable to retire by rotation.
Shareholding in SeQuent Scientific Limited as on the date of notice	Nil
Details of remuneration sought to be paid and the remuneration last drawn.	Please refer explanatory statement against Item No. 7 to this notice of Annual General Meeting along with Annexure B.
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Number of Board Meetings attended during the FY 2024-25	8 of 8
Membership/Chairmanship of the Committees of SeQuent Scientific Limited	1. Risk Management Committee- Member 2. Corporate Social Responsibility Committee- Member 3. Stakeholders Relationship Committee- Member
List of Directorships held in Other Companies	<ul style="list-style-type: none"> • Alivira Animal Health Limited • Sequent Research Limited • Topkim Topkapi ilac Premiks Sanayi Ve Ticaret Anonik Sirketi • Provet Veterinary Ürünleri San. Ve Tic. A. Ş. • Vila Viña Participaciones S.L. • Laboratorios Karizoo, S.A
Membership/ Chairmanship of Committees of other Companies	Memberships: - Alivira Animal Health Limited (Corporate Social Responsibility Committee) Chairmanships: - Alivira Animal Health Limited (Banking Committee)
Listed entities from which the appointee has resigned in the past 3 years:	Resigned from Sanofi India Limited (10 th April, 2022)



b. Details of Mr. Neeraj Bharadwaj, Director of the Company:

Name of the Director	Neeraj Bharadwaj
DIN	01314963
Age	56
Nationality	Indian
Date of first appointment on the Board	August 17, 2020
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>Mr. Neeraj Bharadwaj served as Managing Director of Carlyle India Advisors Private Limited till December 2024 which, focused on large growth capital and buyout opportunities across sectors in India.</p> <p>Prior to joining Carlyle in 2012, Mr. Bharadwaj was a Managing Director with Accel Partners' growth investing operation in India. Preceding that he was with Apax Partners for nearly 10 years – he was a Partner in the U.S. and subsequently Managing Director/Country Head for Apax in India, where he led the India operations.</p> <p>He holds an MBA with distinction from Harvard Business School and graduated Summa Cum Laude with a BS in Economics from the Wharton School, University of Pennsylvania, USA.</p>
Terms and conditions of appointment or Reappointment	Non-Executive Non-Independent Director Liable to retire by rotation
Shareholding in SeQuent Scientific Limited as on the date of notice	Nil
Details of remuneration sought to be paid and the remuneration last drawn.	<p>Remuneration shall be paid as per the Policy on Director's Appointment and Remuneration and approval of the shareholders for payment of remuneration to Non-Executive Directors.</p> <p>The details of remuneration paid to him are provided in the Report on Corporate Governance for FY 2024-25.</p>
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Number of Board Meetings attended during the FY 2024-25	8 of 8
Membership/Chairmanship of the Committees of SeQuent Scientific Limited	<ol style="list-style-type: none"> 1. Audit committee- Member 2. Risk Management Committee - Chairman 3. Nomination and Remuneration Committee - Member
List of Directorships held in Other Companies	<ul style="list-style-type: none"> • Piramal Pharma Limited • Nxtra Data Limited • Hexaware Technologies Limited • Indegene Limited • Viyash Life Sciences Private limited • Ver Se Innovation Private limited • VLCC Health Care Limited • Saama Technologies, LLC, USA
Membership/ Chairmanship of Committees of other Companies	<p>Memberships:</p> <ul style="list-style-type: none"> - Piramal Pharma Limited (Risk Management Committee) - Nxtra Data Limited (Nomination and Remuneration Committee) - Hexaware Technologies Ltd. (Corporate Social Responsibility committee, Environmental, Social and Governance Committee, Nomination and Remuneration Committee) - Indegene Limited (Nomination and Remuneration Committee) - Saama Technologies, LLC, USA (Nomination and Remuneration Committee)
Listed entities from which the appointee has resigned in the past 3 years:	Resigned from Piramal Pharma Limited (14 th May, 2025)

c. Details of Dr. Kamal Sharma, Director of the Company:

Name of the Director	Dr. Kamal Sharma
DIN	00209430
Age	77
Nationality	Indian
Date of first appointment on the Board	August 25, 2020
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>Dr. Kamal Sharma has over five decades of professional experience in executive positions in the Chemical and Pharmaceutical industries and has essayed a wide variety of roles in operations, corporate development and executive management. As the Managing Director of Lupin for a decade between 2003-13, he was instrumental in Lupin achieving leadership position in key markets and businesses, transforming it into one of the largest and fastest growing pharmaceutical companies globally. Previously, he also served as President & Chief Executive of the Life Sciences and speciality group and Member of the Management Board at RPG Enterprises.</p> <p>Mr. Sharma received a bachelor's degree in chemical engineering from IIT Kanpur, a post graduate diploma in Industrial Management from Jamnalal Bajaj Institute of Management Studies and a PhD in Economics from IIT, Mumbai. He has also attended Advanced Management Program (AMP) at Harvard Business School, Boston.</p>
Terms and conditions of appointment or Reappointment	Non-Executive Independent Director not liable to retire by rotation.
Shareholding in SeQuent Scientific Limited as on the date of notice	Nil
Details of remuneration sought to be paid and the remuneration last drawn.	<p>Remuneration shall be paid as per the Policy on Director's Appointment and Remuneration and approval of the shareholders for payment of remuneration to Independent.</p> <p>The details of remuneration paid to him are provided in the Report on Corporate Governance for FY 2024-25.</p>
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Number of Board Meetings attended during the FY 2024-25	8 of 8
Membership/Chairmanship of the Committees of SeQuent Scientific Limited	<ol style="list-style-type: none"> 1. Audit Committee - Member 2. Nomination and Remuneration Committee - Member 3. Corporate Social Responsibility Committee - Chairman
List of Directorships held in Other Companies	<ul style="list-style-type: none"> • Shilpa Medicare Limited • Symed Labs Limited • Faisa Financial Private Limited • Templetree Properties Private Limited • Temple Wellness Ventures India Private Limited • Alivira Animal Health Limited • Viyash Life Sciences Private Limited • Shalina Healthcare DMCC • Alivira Animal Health Limited, Ireland • Laboratorios Karizoo, S.A



Membership/ Chairmanship of Committees of other Indian Companies	Memberships: <ul style="list-style-type: none"> - Shilpa Medicare Limited (Audit Committee, Stakeholders Relationship Committee, Risk Management Committee) Chairmanships: <ul style="list-style-type: none"> - Alivira Animal Health Limited (Corporate Social Responsibility Committee)
Listed entities from which the appointee has resigned in the past 3 years:	<ul style="list-style-type: none"> • Lupin Limited (14th October 2022)
Summary of performance evaluation report	He has made significant contributions during his first term of five years. Based on the evaluation conducted by the Board and the Nomination and Remuneration Committee, his performance reflects strong knowledge, acumen, expertise, and experience. His substantial contributions and consistent time commitment have been duly acknowledged and appreciated.

d. Details of Mr. Milind Sarwate, Director of the Company:

Name of the Director	Mr Milind Sarwate
DIN	00109854
Age	65
Nationality	Indian
Date of first appointment on the Board	August 25, 2020
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>Milind Sarwate, Founder of Increate, is an Advisor, Mentor, Independent Director, & ESG Contributor.</p> <p>Increate (meaning "Uncreated" or "Undiscovered", increate. in) works towards business and social value creation, with a focus on capability-building, governance & social aspects of ESG.</p> <p>Milind's independent directorships include Asian Paints, Mahindra Finance, CEAT, Nykaa, and Hexaware. He specializes in audit committee roles. He has been on listed company boards since 2005. His previous board memberships include Mindtree and International Paper.</p> <p>His 42-year experience includes long stints as CFO and CHRO in Marico & Godrej.</p> <p>He is a Chartered Accountant, Cost Accountant, Company Secretary, and a CII-Fulbright Fellow.</p>
Terms and conditions of appointment or Reappointment	Non Executive Independent Director not liable to retire by rotation.
Shareholding in SeQuent Scientific Limited as on the date of notice	Nil
Details of remuneration sought to be paid and the remuneration last drawn.	<p>Remuneration shall be paid as per the Policy on Director's Appointment and Remuneration and approval of the shareholders for payment of remuneration to Independent.</p> <p>The details of remuneration paid to him are provided in the Report on Corporate Governance for FY 2024-25.</p>
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Number of Board Meetings attended during the FY 2024-25	8 of 8
Membership/Chairmanship of the Committees of SeQuent Scientific Limited	<ol style="list-style-type: none"> 1. Audit Committee- Chairman 2. Nomination and Remuneration Committee- Chairman 3. Stakeholders Relationship Committee- Member 4. Risk Management Committee- Member

List of Directorships held in Other Companies	<ul style="list-style-type: none"> • Mahindra & Mahindra Financial Services Ltd • Hexaware Technologies Limited • FSN E-Commerce Ventures Limited • CEAT Limited • Asian Paints Limited • OmniActive Health Technologies Limited • WheelsEMI Pvt Ltd.
Membership/ Chairmanship of Committees of other Indian Companies	<p>Memberships:</p> <ul style="list-style-type: none"> - Asian Paints Limited (Risk Management Committee) - CEAT Limited (Risk Management Committee & Sustainability and CSR Committee) - FSN E-Commerce Ventures Limited (Fundraise & Investment Committee) - Hexaware Technologies Limited (Risk Management Committee) - Mahindra & Mahindra Financial Services Ltd (Asset Liability Committee, Audit Committee, Digital & AI Committee, Nomination & Remuneration Committee, Risk Management Committee, Special Committee for Monitoring and Follow-up of Frauds) - OmniActive Health Technologies Limited (Audit Committee) - WheelsEMI Pvt. Ltd. (Nomination & Remuneration Committee) <p>Chairmanships:</p> <ul style="list-style-type: none"> - Asian Paints Limited (Audit Committee) - CEAT Limited (Audit Committee) - FSN E-Commerce Ventures Limited (Audit Committee) - Hexaware Technologies Limited (Audit Committee, Nomination and Remuneration Committee and ESG Committee) - Mahindra & Mahindra Financial Services Ltd (Committee for Strategic Investments, IT Strategy Committee) - OmniActive Health Technologies Limited (Nomination & Remuneration Committee) - WheelsEMI Pvt. Ltd. (Audit Committee)
Listed entities from which the appointee has resigned in the past 3 years:	<ul style="list-style-type: none"> • Metropolis Healthcare Limited (6th September 2023)
Summary of performance evaluation report	<p>He has made significant contributions during his first term of five years. Based on the evaluation conducted by the Board and the Nomination and Remuneration Committee, his performance reflects strong knowledge, acumen, expertise, and experience. His substantial contributions and consistent time commitment have been duly acknowledged and appreciated.</p>



Relevant details pursuant to Secretarial Standard on General Meetings issued by Institute of Company Secretaries of India, is as given under:

a. Details of Dr. Fabian Kausche, Director of the Company:

Name of the Director	Dr. Fabian Kausche
DIN	08976500
Age	63
Nationality	American
Date of first appointment on the Board	December 14, 2020
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>Dr. Fabian Kausche is currently Deputy Director General for Research and Innovation at the International Livestock Research Institute (ILRI) a non-governmental organization based in Nairobi, Kenya. He concurrently serves on the board of Pet Flavors, LLC Melbourne, Florida. He also owns and runs FK Consulting, LLC a company located in Atlanta specializing in supporting animal health companies in product innovation and organizational efficiency strategies and works as scientific advisor for Rejuvenate Bio a California-based startup that develops modern gene therapies for companion animals and as special advisor for FidoCure a startup company researching treatments for cancer in dogs using artificial intelligence. He was chairman of the board for PetMedix a UK-based startup developing monoclonal antibodies for pets until it's successful exit and sale to Zoetis.</p> <p>Dr. Kausche held subsequent positions as Global Head of Research & Development for three of the top eight global Animal Health companies: Novartis Animal Health, Merial, and Boehringer Ingelheim Animal Health where led the post-merger integration of the largest R&D organization in the Animal Health industry with more than 1,200 scientist and support staff. In addition to his extensive Animal Health R&D experience, he gained additional expertise in the human health space as head of R&D for Novartis Consumer Health. Prior to that, he also successfully led a companion animal sales force for Novartis Animal Health.</p> <p>Dr. Kausche received a veterinary degree from the Hannover Veterinary School. He subsequently completed a Master of Science degree at Iowa State University. Dr. Kausche also took part in a research program that led him to receiving the German PhD (Dr.med.vet.) in a combination program between the Hannover Medical and Veterinary Schools. Having completed the Advanced Management Program in 2005, he is also an alumnus of Harvard Business School.</p>
Terms and conditions of appointment or Reappointment	Non-Executive Non-Independent Director Liable to retire by rotation.
Shareholding in SeQuent Scientific Limited including shareholding as a beneficial owner as on the date of notice	Nil
Details of remuneration sought to be paid and the remuneration last drawn.	<p>Remuneration shall be paid as per the Policy on Director's Appointment and Remuneration and approval of the shareholders for payment of remuneration to Independent.</p> <p>The details of remuneration paid to him are provided in the Report on Corporate Governance for FY 2024-25.</p>
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Number of Board Meetings attended during the FY 2024-25	7 of 8

Membership/Chairmanship of the Committees of SeQuent Scientific Limited	Nil
List of Directorships held in Other Companies	<ul style="list-style-type: none"> • GALVmed Ltd • Rejuvenate Bio • Pet Flavors, LLC Melbourne, Florida • Novobind • FidoCure
Membership/ Chairmanship of Committees of other Companies	Memberships: <ul style="list-style-type: none"> - GALVmed Ltd (Scientific and technical committee) - Rejuvenate Bio (Scientific Advisory Committee) - Novobind (Advisory Committee)
Listed entities from which the appointee has resigned in the past 3 years:	Nil

b. Details of Mr. Gregory John Andrews, Director of the Company:

Name of the Director	Mr. Gregory John Andrews
DIN	08904518
Age	64
Nationality	Australian
Date of first appointment on the Board	October 07, 2020
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>Greg is a multi-disciplinary executive with 40 years of commercial experience in the pharmaceutical industry. He is a dynamic business leader who creates a positive impact on the business environment through change and active engagement of both internal and external stakeholders.</p> <p>Marketing, communications and management are his core disciplines.</p> <p>Greg has led many marketing teams in the USA and Europe and most recently was the Global Marketing Director for Virbac. He headed global Public Affairs and Policy for Pfizer Animal Health during its IPO transition to Zoetis. Greg also held numerous senior management roles within the animal health industry including country and regional management in Europe, Africa, Middle East, Russia and CIS. He currently acts as an animal health consultant.</p> <p>Greg received a Bachelor of Science (Hons) from Monash University, Australia and Post Graduate Diplomas in both Business Management and International Relations from the University of Tasmania, Australia.</p>
Terms and conditions of appointment or Reappointment	Non-Executive Non-Independent Director Liable to retire by rotation.
Shareholding in SeQuent Scientific Limited including shareholding as a beneficial owner as on the date of notice	Nil
Details of remuneration sought to be paid and the remuneration last drawn.	<p>Remuneration shall be paid as per the Policy on Director's Appointment and Remuneration and approval of the shareholders for payment of remuneration to Independent.</p> <p>The details of remuneration paid to him are provided in the Report on Corporate Governance for FY 2024-25.</p>
Number of Board Meetings attended during the FY 2024-25	8 of 8
Membership/Chairmanship of the Committees of SeQuent Scientific Limited	Nil



List of Directorships held in Other Companies	Nil
Membership/ Chairmanship of Committees of other Companies	Nil
Listed entities from which the appointee has resigned in the past 3 years:	Nil

c. Details of Mr. Hari Babu Bodepudi, Director of the Company:

Name of the Director	Mr. Hari Babu Bodepudi
DIN	01119687
Age	61
Nationality	Indian
Date of first appointment on the Board	August 7, 2023
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>Dr. Hari Babu Bodepudi holds a PhD degree in Organic Chemistry from Andhra University and has over 30 years of Industry experience permeating diverse roles in Research, Manufacturing, Quality and operations in both APIs and Oral Solids.</p> <p>During the last 20 years, he held several leadership roles in technical and commercial operations in Mylan Laboratories, including being the COO of Mylan India, CEO of Mylan India and the Global COO of Mylan.</p> <p>He was responsible for more than 50 Mylan facilities and managing more than 200 APIs and 15000 SKUs of different formulations.</p> <p>At Mylan, he led Mylan's foray into the ARV business and grew that business to over USD800 Million with global leadership (in volume, value and portfolio spread) and more than 50% market share.</p> <p>He has hands-on experience in global supply chain, regulatory, API R&D, quality and Commercial operations.</p>
Terms and conditions of appointment or Reappointment	Non-Executive Non-Independent Director Liable to retire by rotation.
Shareholding in SeQuent Scientific Limited as on the date of notice	Nil
Details of remuneration sought to be paid and the remuneration last drawn.	<p>Remuneration shall be paid as per the Policy on Director's Appointment and Remuneration and approval of the shareholders for payment of remuneration to Independent.</p> <p>The details of remuneration paid to him are provided in the Report on Corporate Governance for FY 2024-25.</p>
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Number of Board Meetings attended during the FY 2024-25	6 of 8
Membership/Chairmanship of the Committees of SeQuent Scientific Limited	Nil
List of Directorships held in Other Companies	<ul style="list-style-type: none"> • Symed Labs Limited • Vindhya Pharma (India) Private Limited • Appcure Labs Private Limited • Viyash Life Sciences Private Limited
Membership/ Chairmanship of Committees of other Indian Companies	<p>Chairmanships:</p> <ul style="list-style-type: none"> - Viyash Life Sciences Private Limited (CSR Committee) - Symed Labs Limited (CSR Committee)
Listed entities from which the appointee has resigned in the past 3 years:	Nil

d. Details of Ms. Revati Parag Kasture, Director of the Company:

Name of the Director	Ms. Revati Parag Kasture
DIN	07558973
Age	54
Nationality	Indian
Date of first appointment on the Board	December 17, 2024
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>Ms. Revati Kasture has over two decades of experience in ratings and research. She is currently the Executive Director (under organization nomenclature) of Care Ratings Limited and CEO of CareEdge Global IFSC Limited (CGIL), a wholly owned subsidiary of Care Ratings.</p> <p>Prior to this she headed the Criteria and Policy Department at CARE Ratings which entailed development of rating criteria, policy and rating models, process improvements as well as interacting with regulators. In the span of her career, she has managed multiple departments within CARE including the large corporate ratings, incubation and scale-up of industry research department making it a profit Centre.</p> <p>Ms. Kasture is an all-India merit rank holder Chartered Accountant and Cost Accountant and has been honored with Professional Achiever- Woman award by the Institute of Chartered Accountants of India in December 2011. She is also awarded as one of India's top 100 "Women in Finance" in Leading Category in March 2019.</p>
Terms and conditions of appointment or Reappointment	Non-Executive Independent Director not liable to retire by rotation.
Shareholding in SeQuent Scientific Limited including shareholding as a beneficial owner as at the date of notice	Nil
Details of remuneration sought to be paid and the remuneration last drawn.	<p>Remuneration shall be paid as per the Policy on Director's Appointment and Remuneration and approval of the shareholders for payment of remuneration to Independent.</p> <p>The details of remuneration paid to her are provided in the Report on Corporate Governance for FY 2024-25.</p>
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Number of Board Meetings attended during the FY 2024-25	1 of 1
Membership/Chairmanship of the Committees of SeQuent Scientific Limited	<p>1. Audit Committee- Member</p> <p>2. Stakeholder's Relationship Committee- Chairperson</p>
List of Directorships held in Other Companies	Nil
Membership/ Chairmanship of Committees of other Indian Companies	Nil
Listed entities from which the appointee has resigned in the past 3 years:	Nil



ANNEXURE – B

STATEMENT PURSUANT TO PART II OF SCHEDULE V TO THE COMPANIES ACT, 2013 IN RESPECT OF ITEM NOS. 6 AND 7 OF THE NOTICE

1. General Information:

a. Nature of Industry:

The Company is India's leading animal health company, ranked among the top 20 animal health companies in the world. The Company, along with its subsidiaries, operates in over 90 countries and has 7 manufacturing facilities, serving consumers worldwide. Our comprehensive offering, includes Active Pharmaceutical Ingredients (API), finished dosage formulations (FDF), and analytical services, caters to the global needs of animal health.

b. Date or expected date of Commencement of Commercial production:

Not applicable as the Company is an existing Company

In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:

Not Applicable as the Company is an existing Company

c. Financial performance based on given indicators of the Company:

Particulars	₹ In Million		
	For the year ended March 31, 2025	For the year ended March 31, 2024	For the year ended March 31, 2023
Total income	2291.94	2144.98	2509.27
Profit / (Loss) before tax	220.48	(2.39)	(97.46)
Profit / (Loss) after tax	157.94	6.22	(60.80)

d. Foreign Investment or collaborations, if any:

The foreign investment in the Company is 52.61% of the Paid-up Share Capital of the Company as on March 31, 2025. The Company does not have any foreign collaborations.

2. Information about the appointee

a. Background details:

Brief profile of Rajaram:

With over 30 years of experience, Mr. Rajaram has a strong track record of leading revenue and profitability growth across multiple industries including pharmaceuticals. He joined from Sanofi India Limited, where he was the Managing Director and Country Chair for India. At Sanofi, he led the strategic reorientation of its India business operations, resulting in accelerated growth in key therapies and significant transformation of Sanofi's market operations. Before this, he was Chief Marketing Officer at Airtel, India's leading telecommunications company. Rajaram started his career at Hindustan Unilever Ltd., where he held various leadership roles in India and other Asian markets for over 18 years, building and managing many iconic consumer brands.

Mr. Rajaram holds a Degree of BE (Hons)-Electrical & Electronics from Birla Institute of Technology and Science, Pilani, and MBA from Indian Institute of Foreign Trade, New Delhi. He has completed the Advanced Management Program from Harvard Business School, USA

Past remuneration, recognition or awards:

In the financial year 2024-25, remuneration of Mr. Rajaram Narayanan was ₹19.87 Million from the Company. Further, he had additionally received remuneration of ₹29.36 Million from Alivira Animal Health Limited, a wholly owned subsidiary of the Company.

b. Job Profile and suitability:

Considering Mr. Rajaram's solid track record of successfully transforming businesses in highly complex and regulated industries, the Board believes that his strategic vision as well as operational expertise and rigor will be pivotal for the Company's next phase of growth and success. Following are his key achievements in the Company:

- ✓ Growth in financials
- ✓ Product Expansion across geographies
- ✓ Restructuring of business
- ✓ Awards and recognitions for Company
- ✓ Shareholders Value Creation

c. Increment in Remuneration proposed:

As provided in Item No. 7 of Explanatory Statement to this Notice.

d. Comparative remuneration profile with respect to industry, size of the company, profile of the position and person:

The remuneration payable to Mr. Rajaram has been benchmarked with the remuneration being drawn by other managerial personnel in the similar capacity of other Companies of comparable size in the pharmaceutical industry. Considering the general industry and the specific Company profile, the remuneration is in line with the industry levels and that of comparatively placed companies in India.

e. Pecuniary relationship directly or indirectly with the company or relationship with the managerial personnel, if any:

Mr. Rajaram has no other pecuniary relationship with the Company except to the extent of his remuneration from the Company.

f. Profile and other disclosures of the Non-Executive Directors (including Independent Directors):

The brief profile of Non Executive Directors (Including Independent directors), along with past and proposed remuneration can be referred to in Annexure-A. Basis their contribution in the Company, the Company believes that the proposed remuneration to the Non-Executive Directors is commensurate with the remuneration paid by similar size of companies with similar complexities.

There is no other pecuniary relationship with the Company for the managerial person except to the extent of remuneration to be received from the Company.

3. Other Information:**Reasons of loss or inadequate profits, steps taken or proposed to be taken for improvement and expected increase in productivity and profits in measurable terms:**

The Company is proactively implementing strategic initiatives aimed at enhancing future performance. Efforts are underway to drive organizational and operational efficiencies, reinforce core competencies, and strengthen financial resilience. Key focus areas include profit optimization, prudent cash management, improved operational execution, and effective cost and working capital control.

The Company is focused on growth by expanding into new markets and increasing its international presence. It is also accelerating research and development in our businesses to create future pipeline of new products to drive consistent growth.



ANNEXURE-C

General instructions for accessing and participating in the AGM through Video Conference/ Other Audio-Visual Means (VC/ OAVM) Facility and voting through electronic means including remote e-Voting

1. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
2. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
3. Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of the Listing Regulations (as amended), and the Circulars, the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as venue voting on the date of the AGM will be provided by NSDL.
4. In line with the Circulars, the Notice calling the AGM has been uploaded on the website of the Company at <https://www.sequent.in/>. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.
5. EGM/AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular issued from time to time

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

The remote e-voting period begins on August 4, 2025, at 09:00 A.M. and ends on August 7, 2025, at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. August 1, 2025, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being August 1, 2025.

Any person holding shares in physical form and non-individual shareholders, who acquires shares of the Company and becomes member of the Company after the notice is sent through e-mail and holding shares as of the cut-off date i.e. August 1, 2025, may obtain the login ID and password by sending a request at evoting@nsdl.com or Issuer/RTA. However, if you are already registered with NSDL for remote e-voting, then you can use your existing user ID and password for casting your vote. If you forgot your password, you can reset your password by using "Forgot User Details/Password" or "Physical User Reset Password" option available on www.evoting.nsdl.com or call on 022 - 4886 7000. In case of Individual Shareholders holding securities in demat mode who acquires shares of the Company and becomes a Member of the Company after sending of the Notice and holding shares as of the cut-off date i.e. August 1, 2025, may follow steps mentioned in the Notice of the AGM under "Access to NSDL e-Voting system".

How do I vote electronically using NSDL e-Voting system?





The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<ol style="list-style-type: none"> For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Shareholders/Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience.
	<p>NSDL Mobile App is available on</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>App Store</p> </div> <div style="text-align: center;">  <p>Google Play</p> </div> </div> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 10px;">   </div>



Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with CDSL	<ol style="list-style-type: none">1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi / Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password.2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option.3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option.4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***.

5. Password details for shareholders other than Individual shareholders are given below:
 - a. If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b. If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
 - c. How to retrieve your 'initial password'?
 - (i). If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8-digit of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - (ii). If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
 - a) Click on "Forgot User Details/Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.



Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/ JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to <Please mention the e-mail ID of Scrutinizer> with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on: 022 - 4886 7000 or send a request to (Name of NSDL Official) at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to investorrelations@sequent.in.
2. In case shares are held in demat mode, please provide DPID-CLID (16-digit DPID + CLID or 16-digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to investorrelations@sequent.in. If you are an Individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.
3. Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM" placed under "**Join meeting**" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at investorrelations@sequent.in. The same will be replied by the company suitably.

Instructions for Members for Attending the AGM Through VC / OAVM are as under:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-voting system. Members may access by following the steps mentioned above for Access to NSDL e-voting system. After successful login, you can see link of "VC/OAVM link" placed under "Join meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-voting or have forgotten the User ID and Password may retrieve the same by following the remote e-voting instructions mentioned in the notice to avoid last minute rush.
2. Facility of joining the AGM through VC / OAVM shall open 30 minutes before the time scheduled for AGM and will be available for Members on first come first served basis.
3. Members are encouraged to join the Meeting through Laptops for better experience.
4. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
5. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
6. Members facing any technical issue in login before / during the AGM can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000.
7. Members who would like to express their views/ask questions as a speaker at the Meeting may pre-register themselves by sending a request from their registered e-mail address mentioning their names, DP ID and Client ID/folio number, PAN and mobile number at investorrelations@sequent.in between August 4, 2025 (9.00 a.m. IST) to August 6, 2025 (5.00 p.m. IST). Only those Members who have pre-registered themselves as a speaker will be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.
8. Members attending the AGM through VC/OAVM shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.